Fernblock®, the main ingredient of Heliocare Oral, demonstrates its effectiveness against melasma
Cantabria Labs. 20/07/2018
A new study has shown that Fernblock®, the main ingredient of Heliocare Oral and unique technology of Cantabria Labs, improves the results of treatment of melasma by accelerating and optimising its effects as published in the American Journal of Clinical and Aesthetic Dermatology.
Investigators of the National Skin Center of Singapore have shown that the use of Fernblock® oral combined with standard therapy for melasma can help reduce the extension and intensity of lesions more quickly and effectively.
The study involved 33 Asian women with melasma aged between 25 and 55 years. The women were divided into two study groups, one treated with hydroquinone 4%, (an effective anti-melasma and anti-skin spot drug product) and sunscreen SPF 50 and the other with hydroquinone 4%, sunscreen SPF 50 and oral Fernblock®.
After 60 days, the use of Fernblock® oral combined with hydroquinone 4% and sunscreen 50 SPF gave significantly better results than hydroquinone 4% and sunscreen 50 SPF alone. Furthermore, Fernblock® contributed to a faster and greater reduction in the extension and intensity of the melasma.
The investigators concluded that the antioxidant and photoprotection properties of Fernblock® make it an invaluable adjuvant for skin depigmentation and anti-melasma treatment regimes. This further highlights the innovation, efficacy and endorsement behind Cantabria Labs products thanks to its exclusive patented technologies.
Drs. Goh, Chuah, and Thng are with the National Skin Centre in Singapore. Drs. Vitale and Delgado are with the R&D Department at Industrial Farmacéutica Cantabria (IFC), SA in Madrid, Spain. Trial Registry: NHG Domain Specific Review Board (DSRB); Trial Registration Number: 2013/00237